{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-059821","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.323346+00:00","generated_at":"2026-05-31T22:59:19.956970+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15","bullets":["License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.","Agreement includes initial and annual fees from low to mid five figures, milestone payments, and royalties on net revenues.","Silo submitted a pre-IND briefing package to FDA and plans 505(b)(2) pathway to shorten clinical timelines and reduce costs.","Term runs per country/product until later of patent expiry, 20 years after first commercial sale, or end of market exclusivity.","CEO Eric Weisblum states the license is a critical step that could increase shareholder value subject to FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-059821","json":"https://secwatch.observer/filing/0001213900-24-059821.json","markdown":"https://secwatch.observer/filing/0001213900-24-059821.md","text":"https://secwatch.observer/filing/0001213900-24-059821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024059821/0001213900-24-059821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024059821/ea0209059-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:59:19.956970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}